PTPRA — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1731562	0.48	4/20
SCHEMBL1731564	0.48	4/20
SCHEMBL1730757	0.45	4/20
SCHEMBL1732660	0.45	4/20
SCHEMBL1732891	0.45	4/20
SCHEMBL1732367	0.44	4/20
SCHEMBL1732436	0.43	4/20
SCHEMBL1732438	0.43	4/20
SCHEMBL875205	0.48	3/20
SCHEMBL611492	0.48	3/20
SCHEMBL1732761	0.45	3/20
SCHEMBL1732762	0.45	3/20
SCHEMBL1239567	0.48	2/20
SCHEMBL614118	0.48	2/20
SCHEMBL874565	0.45	2/20
SCHEMBL611071	0.44	2/20
SCHEMBL613639	0.42	2/20
SCHEMBL145392	1.00	1/20
SCHEMBL1580111	0.82	1/20
SCHEMBL1580112	0.82	1/20

Clinical trials — most relevant to PTPRA by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Regulatory Lymphocytes in Patients Treated With Specific Immunotherapy	PHASE4	COMPLETED
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia	PHASE3	RECRUITING
Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF	PHASE3	COMPLETED
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease	PHASE3	RECRUITING
Imatinib in Dermatofibrosarcoma Protuberans (DFSP)	PHASE1/PHASE2	COMPLETED
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation	PHASE2	UNKNOWN
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)	PHASE1/PHASE2	WITHDRAWN
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer	PHASE2	COMPLETED
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Cyclosporine For The Treatment Of COVID-19(+)	PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas	PHASE1	COMPLETED
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)	PHASE1	COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies	PHASE1	ACTIVE_NOT_RECRUITING
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia	PHASE1	COMPLETED
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma	PHASE1	SUSPENDED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure	nan	UNKNOWN
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.	nan	COMPLETED
Longitudinal Prognosis of Lymphoproliferative Manifestations in Primary Immunodeficiencies	nan	NOT_YET_RECRUITING
Evaluation of the Level of Expression of CD45RC on T Lymphocytes as a Predictive Biomarker of Acute Rejection After Renal Transplantation	nan	RECRUITING
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia	nan	UNKNOWN
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
Expression of CD19 Complex in Lymphoproliferative Disorders	nan	UNKNOWN
Using of Costimulatory and co Inhibatory Immune Checkpoints as Diagnostic and Prognostic in Breast Cancer	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a PTPRA binder may also engage these)

Protein	Name	Similarity
Q03348	—	1.000	Q03348 →
P18052	—	1.000	P18052 →
B2GV87	—	0.998	B2GV87 →
P49446	—	0.997	P49446 →
PTPRE	Receptor-type tyrosine-protein phosphatase epsilon	0.996	landscape →
P29351	—	0.991	P29351 →
PTPN6	Tyrosine-protein phosphatase non-receptor type 6	0.991	landscape →
P35234	—	0.990	P35234 →
P41499	—	0.988	P41499 →
P04157	—	0.988	P04157 →
P35235	—	0.987	P35235 →
Q5I142	—	0.987	Q5I142 →
Q5I145	—	0.986	Q5I145 →
Q90687	—	0.986	Q90687 →
PTPN11	Tyrosine-protein phosphatase non-receptor type 11	0.985	landscape →
P81718	—	0.985	P81718 →
O55082	—	0.985	O55082 →
Q5I141	—	0.984	Q5I141 →
Q641Z2	—	0.983	Q641Z2 →
PTPRR	Receptor-type tyrosine-protein phosphatase R	0.983	landscape →
Q4JDL3	—	0.982	Q4JDL3 →
Q5I143	—	0.982	Q5I143 →
Q60629	—	0.981	Q60629 →
O35239	—	0.981	O35239 →
P49445	—	0.981	P49445 →
Q5I147	—	0.981	Q5I147 →
PTPRM	Receptor-type tyrosine-protein phosphatase mu	0.980	landscape →
PTPN9	Tyrosine-protein phosphatase non-receptor type 9	0.980	landscape →
Q9IBD8	—	0.980	Q9IBD8 →
PTPN7	Tyrosine-protein phosphatase non-receptor type 7	0.980	landscape →